Selected CYP2D6 Substrates/Mirabegron
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Mirabegron may increase the amount of flecainide, propafenone or thioridazine in your blood by slowing down how quickly your liver processes these medicines.
What might happen:
You could have a change in your heart rhythm or an irregular heartbeat, which may be life-threatening.
What you should do about this interaction:
Contact your healthcare professionals (e.g. doctor of pharmacist) about taking these medications together. Let your doctor know right away if you notice an irregular heartbeat of have dizziness or fainting episodes. Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Myrbetriq (mirabegron) prescribing information. Astellas Pharma Technologies, Inc. June 2012.
2.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
3.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.